Replies to post #774111 on NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

Yes the problem is they will need patient level data from external control arm also for FDA, not just the patients in compassionate use arm. 

[ATLnsider]

I agree GPha, I also believe that NWBio will be able to use RWD from treating other solid tumor cancers from Compassionate Use, Specials Program and Expanded Access.

This RWD could be used to help support label expansion beyond just treating malignant glioma patients, to include all or most solid tumor cancers.